Eisai and Biogen to Continue Phase 2 Alzheimer’s Therapy Trial for Six More Months

Eisai and Biogen to Continue Phase 2 Alzheimer’s Therapy Trial  for Six More Months
Eisai and Biogen had hoped that using an advanced statistical method to analyze Phase 2 clinical trial results would show at 12 months rather than the normal 18 that their Alzheimer’s therapy BAN2401 was effective. But an independent trial review body declared the 12-month results inconclusive, so the Japanese and American partners have announced that they will continue

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *